We are advised by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. that journalists and other readers should disregard the news release, “Third Indication for Kelun-Biotech’s TROP2 ADC Sac-TMT Approved for Marketing by NMPA in EGFRm NSCLC Following Progression on EGFR-TKI Therapy”, issued 11-Oct-2025 over PR Newswire, as the release contained erroneous information. (Kelunbiotech said a revised release will be issued later. )
SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
https://rt.newswire.ca/rt.gif?NewsItemId=CN95771&Transmission_Id=202510110736PR_NEWS_USPR_____CN95771A&DateId=20251011
COMTEX_469450959/1005/2025-10-11T07:37:16